For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
"Delivery of this report will take 1-3 days after purchase."
The Global Immunology Partnering 2012-2018: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the immunology/autoimmune partnering deals and agreements entered into by the worlds leading healthcare companies
Global Immunology Partnering 2012 to 2018 provides the full collection of Immunology disease deals signed between the world's pharmaceutical and biotechnology companies since 2012.
Trends in Immunology partnering deals
Financial deal terms for headline, upfront and royalty by stage of development
Immunology partnering agreement structure
Immunology partnering contract documents
Top Immunology deals by value
Most active Immunology dealmakers
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Immunology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Immunology deals.
The report presents financial deal terms values for Immunology deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
The initial chapters of this report provide an orientation of Immunology dealmaking trends.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in Immunology dealmaking since 2012 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
Chapter 4 provides a review of the leading Immunology deals since 2012. Deals are listed by headline value. The chapter includes the top 25 most active Immunology dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides comprehensive access to Immunology deals since 2012 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all Immunology partnering deals by specific Immunology target announced since 2012. The chapter is organized by specific Immunology therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all Immunology partnering deals signed and announced since 2012. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Immunology partnering and dealmaking since 2012.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Immunology technologies and products.
Report scope
Global Immunology Partnering 2012 to 2018 is intended to provide the reader with an in-depth understanding and access to Immunology trends and structure of deals entered into by leading companies worldwide.
Global Immunology Partnering 2012 to 2018 includes:
Trends in Immunology dealmaking in the biopharma industry since 2012
Analysis of Immunology deal structure
Access to headline, upfront, milestone and royalty data
Access to hundreds of Immunology deal contract documents
Comprehensive access to over 3500 Immunology deal records
The leading Immunology deals by value since 2012
Most active Immunology dealmakers since 2012
The report includes deals for the following indications: AIDS, Allergy, Anaphylactic shock, Graft versus host disease, Inflammation, Other autoimmune, Scleroderma, Systemic lupus erythematosus, plus other immunology indications.
In Global Immunology Partnering 2012 to 2018, available deals and contracts are listed by:
Headline value
Upfront payment value
Royalty rate value
Stage of development at signing
Deal component type
Technology type
Specific therapy indication
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Immunology Partnering 2012-2018 report provides comprehensive access to available deals and contract documents for over 700 immunology deals. Analyzing actual contract agreements allows assessment of the following:
What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are the sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Benefits
Global Immunology Partnering 2012 to 2018 provides the reader with the following key benefits:
In-depth understanding of Immunology deal trends since 2012
Access Immunology deal headline, upfront, milestone and royalty data
Research hundreds of actual contracts between Immunology partner companies
Comprehensive access to over 750 links to actual Immunology deals entered into by the world's biopharma companies
Indepth review of Immunology deals entered into by the top 25 most active dealmakers
Benchmark the key deal terms companies have agreed in previous deals
Identify key terms under which companies partner Immunology opportunities
Uncover companies actively partnering Immunology opportunities